887O First multicentric randomized phase II trial investigating the antitumor efficacy of peptide receptor radionucleide therapy with 177Lutetium-Octreotate (OCLU) in unresectable progressive neuroendocrine pancreatic tumor: Results of the OCLURANDOM trial

Publication | Closed Access

DOI

Citations

References

2022

Year

Éric Baudin, Thomas Walter, A. Beron, D. Smith, Julien Hadoux, C. Lachachi, David Taïeb, C. Ansquer, L.O. Dierickx, L. de Mestier du Bourg,

Annals of Oncology

OncologyPhase Ii TrialEngineeringPancreatic CancerMedicineRadionuclide TherapyTheranosticsAntitumor EfficacyOclurandom TrialRadiopharmaceutical TherapyMolecular OncologyPharmacotherapyCancer TreatmentPharmacologyRadiation OncologyNuclear MedicineCancer Research